Pepgen

company

About

PepGen is empowering nucleic acid therapeutics to go the distance.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$112.50M
Industries
Biotechnology,Clinical Trials,Medical
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and they are advancing novel conjugate therapeutics to the clinic.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$157.50M
Pepgen has raised a total of $157.50M in funding over 2 rounds. Their latest funding was raised on Aug 5, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 5, 2021 Series Unknown $112.50M 1 Detail
Dec 9, 2020 Series A $45M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Pepgen is funded by 1 investors. CureDuchenne Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
CureDuchenne Ventures Series Unknown